Healthcare


 Artivion Experiences Strong Surge: Analyst Upgrades Drive Confidence

Artivion Experiences Strong Surge: Analyst Upgrades Drive Confidence

October 23, 2024 11:35 AM PDT| By Team Kalkine Media

Headlines,Artivion shares surged following analyst upgrades.,Research firms forecast optimistic outlook for the company's stock performance.,Increased coverage and positive assessments boost market confidence.,Artivion,(NYSE:AORT),shares experienced...

 Envista Receives Revised Price Target from Stifel Nicolaus

Envista Receives Revised Price Target from Stifel Nicolaus

October 23, 2024 11:33 AM PDT| By Team Kalkine Media

Headlines,Stifel Nicolaus raises Envista's target price to $21.00.,Multiple firms adjust their ratings on Envista.,Revised outlook suggests positive momentum for the company.,Envista,(NYSE:NVST),has received a revised price target from Stifel Nicolau...

 Alto Neuroscience (NYSE: ANRO) Reports Phase 2b Study Results for ALTO-100, Faces Setback in Major Depressive Disorder Treatment

Alto Neuroscience (NYSE: ANRO) Reports Phase 2b Study Results for ALTO-100, Faces Setback in Major Depressive Disorder Treatment

October 22, 2024 10:18 PM PDT| By Team Kalkine Media

Highlights:,ALTO-100 fails to meet primary endpoint in Phase 2b study for major depressive disorder (MDD).,Despite the setback, the treatment shows a favorable safety and tolerability profile.,Alto Neuroscience maintains a strong cash position to sup...

 Can Alto Neuroscience Recover After ALTO-100 Trial Results?

Can Alto Neuroscience Recover After ALTO-100 Trial Results?

October 22, 2024 02:46 PM PDT| By Team Kalkine Media

Highlights,Alto Neuroscience reports Phase 2b trial results for its drug candidate ALTO-100 in treating major depressive disorder.,The trial did not achieve its primary endpoint, but the drug maintained a positive safety profile.,The company continue...

 Will NeoGenomics' Approval Boost Its Market Position?

Will NeoGenomics' Approval Boost Its Market Position?

October 22, 2024 02:35 PM PDT| By Team Kalkine Media

Highlights,NeoGenomics gains conditional approval for advanced cancer tests in New York.,The new assays offer enhanced diagnostic value for various solid tumors.,Approval expands NeoGenomics’ reach to more healthcare providers and patients in New Yor...

 ENDRA Life Sciences Advances Liver Health Technology in Germany

ENDRA Life Sciences Advances Liver Health Technology in Germany

October 22, 2024 01:13 PM PDT| By Team Kalkine Media

Highlights,ENDRA Life Sciences launches a clinical study for its TAEUS liver system in Germany.,The study will evaluate TAEUS’ effectiveness in measuring liver fat against MRI-PDFF.,The initiative supports broader adoption and regulatory approval eff...

 Charles River Laboratories Faces Analyst Scrutiny Amid Stock Decline

Charles River Laboratories Faces Analyst Scrutiny Amid Stock Decline

October 22, 2024 09:20 AM PDT| By Team Kalkine Media

Headlines,Charles River Laboratories Faces Decline Amid Analyst Downgrades,Stock Performance Reflects Mixed Analyst Sentiment,Adjustments in Price Targets Impact CRL's Recent Trading,Charles River Laboratories International,(NYSE:CRL),saw a 4.9% decl...

 Molecular Partners and Orano Med Present Enhanced Preclinical Data for MP0712 at EANM 2024

Molecular Partners and Orano Med Present Enhanced Preclinical Data for MP0712 at EANM 2024

October 22, 2024 04:11 AM PDT| By Team Kalkine Media

Highlights,Molecular Partners AG and Orano Med presented promising preclinical data for their Radio-DARPin Therapeutic candidate, MP0712, at the EANM Congress 2024.,MP0712 demonstrated dose-dependent efficacy, favorable safety profiles, and high spec...

 GRI Bio Confirms Exercise of Warrants

GRI Bio Confirms Exercise of Warrants

October 22, 2024 04:09 AM PDT| By Team Kalkine Media

Highlights,GRI Bio has entered into definitive agreements to exercise existing warrants, allowing the purchase of 762,236 shares at a reduced price.,The company will issue new unregistered Series D-1 and D-2 warrants in conjunction with this exercise...

 Interim Results Indicate Progress in Phase 3 ENSURE Program of Vidofludimus Calcium

Interim Results Indicate Progress in Phase 3 ENSURE Program of Vidofludimus Calcium

October 22, 2024 04:06 AM PDT| By Team Kalkine Media

Highlights,Immunic, Inc. received a positive recommendation from the Independent Data Monitoring Committee for its phase 3 ENSURE program, assessing vidofludimus calcium for relapsing multiple sclerosis.,The ENSURE program remains on schedule for com...

 Noteworthy US Penny Stocks Highlighted for October 2024

Noteworthy US Penny Stocks Highlighted for October 2024

October 22, 2024 03:49 AM PDT| By Team Kalkine Media

Highlights,Mixed performance in the U.S. stock market has led to renewed interest in penny stocks.,A selection of penny stocks exhibiting strong financial health is available for exploration.,Companies in diverse sectors, including transportation, bi...

 Vivos Therapeutics, Inc. (NASDAQ:VVOS) Pioneers Noninvasive Solutions for Sleep Disorders

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Pioneers Noninvasive Solutions for Sleep Disorders

October 22, 2024 01:32 AM PDT| By Team Kalkine Media

Highlights:,Vivos Therapeutics receives new AMA CPT codes for enhanced insurance reimbursement of OSA treatments.,FDA clears Vivos CARE oral devices for effective treatment of sleep apnea in children and adults.,Over 31,000 patients treated globally...

 Could Elevai Biosciences' EL-32 Be Missing the Mark on Addressing Obesity?

Could Elevai Biosciences' EL-32 Be Missing the Mark on Addressing Obesity?

October 21, 2024 03:36 PM PDT| By Team Kalkine Media

Highlights,Elevai Biosciences has released data on a dual-action blocker, EL-32, for muscle and fat composition.,Preclinical studies on aged mice indicated improved strength, motor function, and body composition.,Further animal studies are planned fo...

 How Is BioVie Boosting Its Capital?

How Is BioVie Boosting Its Capital?

October 21, 2024 02:34 PM PDT| By Team Kalkine Media

Highlights,BioVie Inc. launches a registered direct offering, issuing shares at a set price.,The company is also issuing unregistered warrants in a concurrent private placement.,Proceeds will support working capital and general corporate purposes.,Bi...

 PureTech-Founded Seaport Therapeutics Finalizes Oversubscribed Series B Financing Round of $225 Million

PureTech-Founded Seaport Therapeutics Finalizes Oversubscribed Series B Financing Round of $225 Million

October 21, 2024 04:13 AM PDT| By Team Kalkine Media

Highlights,Seaport Therapeutics has successfully closed a $225 million Series B financing round, increasing total capital raised to $325 million since its launch in April 2024.,The financing round was led by General Atlantic, with contributions from...

 Walgreens Stock's Trajectory Considered After 20% Surge

Walgreens Stock's Trajectory Considered After 20% Surge

October 21, 2024 03:57 AM PDT| By Team Kalkine Media

Highlights,Walgreens reported Q4 FY2024 revenue of $37.5 billion and adjusted earnings of $0.39 per share, surpassing previous estimates and leading to a stock surge of over 20%.,The company anticipates fiscal 2025 sales between $147 billion and $151...

 Eli Lilly Earnings Preview: Significant Factors to Monitor

Eli Lilly Earnings Preview: Significant Factors to Monitor

October 21, 2024 03:51 AM PDT| By Team Kalkine Media

Highlights,Eli Lilly and Company (LLY) is set to announce its fiscal third-quarter earnings on October 30, with analysts projecting a significant increase in profit per share compared to the previous year.,The company has consistently surpassed earni...

 Strength Highlighted in Corcept (CORT) with 5.5% Increase

Strength Highlighted in Corcept (CORT) with 5.5% Increase

October 21, 2024 03:46 AM PDT| By Team Kalkine Media

Highlights,Corcept Therapeutics (CORT) shares increased by 5.5% in the latest trading session, closing at $49.75, driven by robust trading volume.,The company’s marketed drug, Korlym, is experiencing strong demand, while a new drug application for re...

 French Government Positioned to Take Stake in Sanofi Unit Post-Private Equity Sale

French Government Positioned to Take Stake in Sanofi Unit Post-Private Equity Sale

October 21, 2024 03:33 AM PDT| By Team Kalkine Media

Highlights,France is poised to acquire a 2% stake in Sanofi SA's consumer healthcare unit, Opella, as part of a €16 billion deal with private equity firm Clayton, Dubilier & Rice (CD&R).,The French government expressed concerns regarding foreign cont...

 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) Celebrates $225 Million Series B Financing for Seaport Therapeutics

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) Celebrates $225 Million Series B Financing for Seaport Therapeutics

October 21, 2024 02:17 AM PDT| By Team Kalkine Media

Highlights:,Seaport Therapeutics secures $225 million in an oversubscribed Series B round, led by General Atlantic.,Total capital raised by Seaport reaches $325 million since its launch in April 2024.,Funding will advance clinical-stage neuropsychiat...

Recent Articles






Investing Tips

Previous Next